Back to results
US 8,999,647 B2Granted
Methods of subclassification of ductal carcinoma in situ of the breast
AssigneeDuke University
InventorJoseph Geradts
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of determining the aggressiveness or indolence of a ductal carcinoma in situ lesion. Also provided are methods of developing treatment plans for subjects with a ductal carcinoma in situ lesion based on the aggressiveness of the lesion.
Claims7
A method of determining the aggressiveness of a ductal carcinoma in situ (DCIS) lesion of the breast comprising:
- (a) detecting the DNA copy number of CELSR1 in a sample from the DCIS lesion of the breast, wherein the DNA copy number is detected by array comparative genomic hybridization (aGCH), quantitative PCR, or in situ hybridization;
- (b) comparing the DNA copy number of CELSR1 in the sample against a normal DNA copy number of CELSR1, wherein the normal DNA copy number of CELSR1 is two;
- (c) determining the aggressiveness of the DCIS lesion based on the comparison in step (b), wherein an increased DNA copy number of CELSR1 is indicative of an indolent DCIS lesion.
Dependencies are inferred from the claim text.